NVCT: Nuvectis Pharma Inc

NVCT新闻

• 12:05 Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
• 12:37 H.C. Wainwright重申Nuvectis Pharma股票评级为"买入"
• 12:35 Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
• 13:09 卡普兰以64,240美元购入Nuvectis Pharma (NVCT)股票
• 13:09 Nuvectis Pharma董事长Bentsur购入价值28,600美元的股份
• 13:06 Nuvectis Pharma董事Sanchez以7.5万美元购入NVCT股票
• 11:37 H.C. Wainwright维持Nuvectis Pharma股票买入评级，目标价10美元
• 11:35 H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
• 12:05 Nuvectis Pharma adds former Intra-Cellular exec to board of directors
• 20:36 Nuvectis initiates phase 1b program for cancer drug NXP900
• 01:57 Nuvectis (NVCT) Q2 Loss Widens 43%
• 14:43 Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright
• 11:49 Nuvectis halts NXP800 development for ovarian cancer, shifts focus
• 12:05 Nuvectis reports positive drug interaction study for cancer drug NXP900
• 13:00 Friday’s Insider Activity: Top Buys and Sells in US Stocks
• 16:29 Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In
• 20:48 Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference